Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Celldex Therapeutics (CLDX)
Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,485,507
  • Shares Outstanding, K 47,264
  • Annual Sales, $ 2,360 K
  • Annual Income, $ -112,330 K
  • 60-Month Beta 2.08
  • Price/Sales 638.27
  • Price/Cash Flow N/A
  • Price/Book 6.05
Trade CLDX with:

Options Overview Details

View History
  • Implied Volatility 49.71% ( +0.76%)
  • Historical Volatility 64.68%
  • IV Percentile 3%
  • IV Rank 3.18%
  • IV High 196.09% on 11/02/23
  • IV Low 44.91% on 11/24/23
  • Put/Call Vol Ratio 0.25
  • Today's Volume 178
  • Volume Avg (30-Day) 279
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 14,847
  • Open Int (30-Day) 16,264

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.81
  • Low Estimate -0.91
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.08 +25.32%
on 11/09/23
33.12 -5.10%
on 12/04/23
+4.93 (+18.60%)
since 11/08/23
3-Month
22.11 +42.15%
on 10/30/23
33.55 -6.32%
on 11/06/23
+2.66 (+9.25%)
since 09/08/23
52-Week
22.11 +42.15%
on 10/30/23
48.40 -35.06%
on 01/18/23
-7.38 (-19.02%)
since 12/08/22

Most Recent Stories

More News
Why Celldex Therapeutics Blasted 13% Higher on Monday

The biotech's CSU treatment advanced in the laboratory.

CLDX : 31.43 (-1.26%)
Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall, Monday, 11/6/2023

Stocks that traded heavily or had substantial price changes on Monday: Freshpet, Celldex Therapeutics rise; TreeHouse Foods, Dish Network fall

CLDX : 31.43 (-1.26%)
THS : 41.67 (-0.69%)
HGV : 39.74 (+2.55%)
DISH : 4.57 (+5.06%)
FRPT : 76.25 (+0.98%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 31.43 (-1.26%)
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 31.43 (-1.26%)
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 31.43 (-1.26%)
TFFP : 0.3624 (+3.54%)
Celldex: Q1 Earnings Snapshot

Celldex: Q1 Earnings Snapshot

CLDX : 31.43 (-1.26%)
Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?

Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....

CLDX : 31.43 (-1.26%)
ICPT : 19.00 (+0.21%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 31.43 (-1.26%)
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 31.43 (-1.26%)
AFMD : 0.4200 (+5.05%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 31.43 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 33.81
2nd Resistance Point 33.24
1st Resistance Point 32.33
Last Price 31.43
1st Support Level 30.85
2nd Support Level 30.28
3rd Support Level 29.37

See More

52-Week High 48.40
Fibonacci 61.8% 38.36
Fibonacci 50% 35.26
Fibonacci 38.2% 32.15
Last Price 31.43
52-Week Low 22.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar